Prognostic factors add criteria to treat Waldenstrom's macroglobulinemia.

被引：0
|
作者：
Morel, P
Duhamel, A
Dimopoulos, M
San Miguel, J
Barlogie, B
Kyle, R
Leblond, V
Dhodapkar, M
Mc Coy, J
Treon, S
Gobbi, PG
Merlini, G
机构：
[1] Hop Schaffner, Lens, France
[2] Univ Hosp, Ctr Etud & Rech Informat Med, Lille, France
[3] Univ Athens, Athens, Greece
[4] Hosp Univ, Salamanca, Spain
[5] Univ Arkansas Med Sci, Little Rock, AR 72205 USA
[6] Mayo Clin, Rochester, MN USA
[7] Hop La Pitie Salpetriere, Paris, France
[8] SW Oncol Grp, Seattle, WA USA
[9] Dana Farber Canc Inst, Boston, MA 02115 USA
[10] IRCCS Policlin San Matteo, Biotechnol Res Labs, Pavia, Italy
[11] Univ Pavia, I-27100 Pavia, Italy
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：261 / 262
页数：2
相关论文
共 50 条
  • [21] Regulation of Histone Deacetylase in Waldenstrom Macroglobulinemia.
    Jia, Xiaoying
    Roccaro, Aldo M.
    Azab, Abdel Kareem
    Ngo, Hai T.
    Sacco, Antonio
    Melhem, Molly R.
    Azab, Feda
    Runnels, Judith
    Burwick, Nicolas
    Quang, Phong
    Husu, Emanuel N.
    Leleu, Xavier
    Anderson, Kenneth C.
    Bradner, James
    Ghobrial, Irene M.
    BLOOD, 2008, 112 (11) : 906 - 906
  • [22] Leptomeningeal Carcinomatosis in a patient with Waldenstrom Macroglobulinemia.
    Atta, Sania
    Iqbal, Adil
    Ahluwalia-Singh, Brij
    NEUROLOGY, 2019, 92 (15)
  • [23] Phenotypic and clinical evidence supports rituximab for Waldenstrom's macroglobulinemia.
    Weber, DM
    Gavino, M
    Huh, Y
    Cabanillas, F
    Alexanian, R
    BLOOD, 1999, 94 (10) : 125A - 125A
  • [24] Activity of alemtuzumab (Mabcampath) in relapsed/refractory Waldenstrom's macroglobulinemia.
    Owen, RG
    Rawstron, AC
    Osterborg, A
    Lundin, J
    Svensson, G
    Hillmen, P
    BLOOD, 2003, 102 (11) : 644A - 645A
  • [25] A Phase II Trial of Ofatumumab In Subjects with Waldenstrom's Macroglobulinemia.
    Furman, Richard R.
    Eradat, Herbert
    Switzky, Julie C.
    Hayman, Suzanne R.
    Hofmeister, Craig C.
    Avignon, Nathalie A.
    Leonard, John P.
    Coleman, Morton
    Liao, Qiming
    Shah, Damini N.
    Brownell-Buttich, Stephanie
    Lisby, Steen
    Lin, Thomas S.
    BLOOD, 2010, 116 (21) : 749 - 750
  • [26] Heavy chain somatic hypermutation status in Waldenstrom's macroglobulinemia.
    Schop, RFJ
    Tschumper, RC
    Jelinek, DF
    Greipp, PR
    Kyle, RA
    Fonseca, R
    BLOOD, 2001, 98 (11) : 154A - 154A
  • [27] Bing-Neel syndrome in a patient with Waldenstrom's macroglobulinemia.
    Pasmans, R.
    Schreuder, T.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 558 - 558
  • [28] Fludarahine, mitoxantrone and dexamethasone in the treatment of refractory Waldenstrom's macroglobulinemia.
    Rauch, A
    Pasion, A
    BLOOD, 1997, 90 (10) : 4139 - 4139
  • [29] Clinical Course and Prognosis of Smoldering (Asymptomatic) Waldenstrom's Macroglobulinemia.
    Kyle, Robert
    Benson, Joanne
    Larson, Dirk
    Therneau, Terry
    Dispenzieri, Angela
    Melton, L. Joseph, III
    Rajkumar, S. Vincent
    BLOOD, 2008, 112 (11) : 936 - 937
  • [30] Activation of NFkB is not a feature of multiple myeloma or Waldenstrom's macroglobulinemia.
    Leitch, D
    Barrans, SL
    Jack, A
    Owen, RG
    BLOOD, 2002, 100 (11) : 395A - 395A
12345